Arcellx, Inc.
ACLX
Rang in Aktien
#2785
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Aktienkurs
$115.07
Zuletzt synchronisiert: 2026-05-15
Marktkapitalisierung
$6.73B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
32.28%
Land
US
Handel Arcellx, Inc. (ACLX)
Kategorie
Healthcare
EPS für Arcellx, Inc. (ACLX)
EPS zum December 2025 TTM: $-4.07
Laut den aktuellen Finanzberichten und dem Aktienkurs von Arcellx, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) $-4.07. Am Ende des Jahres 2023 betrug das EPS $-1.47 ein Rückgang im Vergleich zu dem EPS von 2022, das $-4.28 betrug.
EPS-Verlauf von Arcellx, Inc. von 2018 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $-4.07 | 103.50% |
| 2024 | $-2.00 | 36.05% |
| 2023 | $-1.47 | -65.65% |
| 2022 | $-4.28 | 120.62% |
| 2021 | $-1.94 | 31.97% |
| 2020 | $-1.47 | 182.69% |
| 2019 | $-0.52 | -98.96% |
| 2018 | $-50.17 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | -525.55% |
US
|
|
| $-7.98 | 96.07% |
US
|
|
| $-5.29 | 29.98% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -781.57% |
NL
|
